Background

Qualifications

BPharm
PhD

Memberships

British Association of Cancer Research
International Society of Magnetic Resonance in Medicine

Research

Research Interests

Magnetic Resonance Imaging and Spectroscopy
Positron Emission Tomography

Publications

• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ. Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging. Journal of Clinical Oncology 2003, 21(15), 2831-2842.
• Nielsen FU, Daugaard P, Bentzen L, Stodkilde-Jorgensen H, Overgaard J, Horsman MR, Maxwell RJ. Effect of Changing Tumor Oxygenation on Glycolytic Metabolism in a Murine C3H Mammary Carcinoma Assessed by in Vivo Nuclear Magnetic Resonance Spectroscopy. Cancer Research 2001, 61(13), 5318-5325.
• Maxwell RJ, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM, Wilson J. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR in Biomedicine 2002, 15(2), 89-98.
• Seddon BM, Maxwell RJ , Grimshaw R, Raynaud F, Tozer GM, Workman P, Honess DJ. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical Cancer Research 2002, 8(7), 2323-2335.
• Breidahl T, Nielsen FU, Stodkilde-Jorgensen H, Maxwell RJ, Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: acomparative assessment using MRI and MRS. Acta Oncologica 2006, 45(3), 306-316.
• Senanayake PK, Rogers NJ, Finney KLNA, Harvey P, Funk AM, Wilson JI, O'Hogain D, Maxwell R, Parker D, Blamire AM. A new paramagnetically shifted imaging probe for MRI. Magnetic Resonance in Medicine 2017, 77(3), 1307-1317.
• Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, O'Brien JT, Barker RA, Maxwell RJ, Brooks DJ, Burn DJ. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLE-PD study. Journal of Neurology, Neurosurgery, and Psychiatry 2017, 88(4), 310-316.
• Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, Maxwell R, Stoll EA. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro-Oncology 2017, 19(1), 43-54.
• O'Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, Desouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh D-M, Lacombe D, Lambin P, Lassau N, Leach MO, Lee T-Y, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJM, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, Van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC. Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology 2017, 14(3), 169-186.
• Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine 2017, 30(9), e3736.
• Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemotherapy and Pharmacology 2016, 78(6), 1269-1281.
• Pearson RA, Thelwall PE, Snell J, McKenna J, Pieniazek P, Fitzgerald EL, Heer R, McMenemin RM, Pedley ID, Azzabi AS, Newell H, Maxwell RJ, Plummer ER, Frew JA. Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study. In: 2016 Genitourinary Cancers Symposium. 2016, San Francisco: American Society of Clinical Oncology.
• Pearson RA, Thelwall PE, Snell J, McKenna J, Pieniazek P, Fitzgerald E, Heer R, McMenemin RM, Pedley ID, Azzabi A, Maxwell RJ, Newell DR, Plummer ER, Frew JA. Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study. In: Genitourinary Cancers Symposium 2016. 2016, San Francisco, California: Journal of Clinical Oncology.
• Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. European Journal of Cancer 2016, 56, 69-76.
• Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, Vormoor J, Maxwell RJ, Bacon CM. Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging. PLoS ONE 2014, 9(1), e85128.
• McKay JA, Xie L, Manus C, Langie SAS, Maxwell RJ, Ford D, Mathers JC. Metabolic effects of a high-fat diet post-weaning after low maternal dietary folate during pregnancy and lactation. Molecular Nutrition & Food Research 2014, 58(5), 1087-1097.
• Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice. PLoS ONE 2013, 8(12), e81763.
• Burki U, Blain A, Wilson I, Launay G, Coursindel T, Maxwell R, Carroll M, Laval S, Gait M, Straub V. Development of in vivo imaging techniques to determine the biodistribution of antisense oligonucleotides in dystrophin deficient muscular dystrophy. In: United Kingdom Neuromuscular Translational Research Conference. 2012, Newcastle upon Tyne: Elsevier Ltd.
• Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer 2012, 106(8), 1386-1394.
• Chatterjee S, Frew J, Mott J, McCallum H, Stevenson P, Maxwell R, Wilsdon J, Kelly CG. Variation in Radiotherapy Target Volume Definition, Dose to Organs at Risk and Clinical Target Volumes using Anatomic (Computed Tomography) versus Combined Anatomic and Molecular Imaging (Positron Emission Tomography/Computed Tomography): Intensity-modulated Radiotherapy Delivered using a Tomotherapy Hi Art Machine: Final Results of the VortigERN Study. Clinical Oncology 2012, 24(10), e173-e179.
• Chatterjee S, Frew J, Wilsdon JB, McCallum H, Mott J, Stevenson P, Dobrowsky W, Maxwell RJ, Nutting CM, Kelly CG. Final Results of Vortigern Study: CT Versus Pet-CT Based Tomotherapy Voluming and Dose Escalation in Oropharyngeal Squamous Cell Carcinoma (ISRCTN 33175361, UKCRN ID: 08/h0907/127) [meeting abstract]. Clinical Oncology 2011, 23(3), S26-S26.
• Cox EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. Pre-clinical evaluation of combinations of PI3K & MEK inhibitors in colorectal carcinoma cell lines. In: EJC SUPPLEMENTS. 2010, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND: PERGAMON-ELSEVIER SCIENCE LTD.
• Chatterjee S, Frew J, Wilsdon JB, Mccallum HM, Mott JH, Stevenson P, Dobrowsky W, Maxwell RJ, Kelly CG. VortigERN: Variation of radiotherapy target volume definintion, dose to organs at risk (OAR), and clinical target volumes using anatomic (CT)versus combined anatomic and molecular imaging (PET-CT): Intensity-modulated radiotherpay delivered using a tomotherapy hi art machine. In: 2010 ASCO Annual Meeting. 2010, Chicago, USA: American Society of Clinical Oncology.
• Wood KA, Honess DJ, Maxwell RJ, Paul RL, Wilson J, Locke RJ, O'Doherty MJ, Marsden P, Blower PJ, Saunders MI. Preliminary microscopic evaluation of 64CuATSM as a PET radiotracer for tumour hypoxia. In: EJC SUPPLEMENTS. 2007, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND: PERGAMON-ELSEVIER SCIENCE LTD.